Climb Bio (CLYM) Net Cash Flow (2020 - 2026)

Climb Bio's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$27.3 million for Q1 2026.

• Quarterly Net Cash Flow rose 53.03% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.7 million (up 72.8% YoY) and the FY2025 annual result came in at -$51.5 million, down 769.94% from the prior year.
• Net Cash Flow was -$27.3 million for Q1 2026 at Climb Bio, down from $9.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $118.1 million in Q2 2024 and bottomed at -$77.1 million in Q3 2024.
• A 5-year average of -$2.3 million and a median of $1.7 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 654.12% — and 2024, when it soared 1337.58%.
• Climb Bio's Net Cash Flow stood at $5.8 million in 2022, then jumped by 519.13% to $36.1 million in 2023, then sank by 263.18% to -$58.9 million in 2024, then surged by 116.78% to $9.9 million in 2025, then tumbled by 376.55% to -$27.3 million in 2026.
• Business Quant data shows CLYM's Net Cash Flow at -$27.3 million in Q1 2026, $9.9 million in Q4 2025, and $3.1 million in Q3 2025.